LQDA Liquidia Corp

company

SEC Filings & Insider Trading Activity 2026

Business Overview

• • Core business model: Development and commercialization of inhaled treprostinil therapies for PAH and PH-ILD leveraging proprietary PRINT particle engineering technology
• • New product launch: FDA approved and commercialized YUTREPIA inhalation powder in May-June 2025, designed for higher dosing and improved lung delivery
• • Strategic emphasis: Positioning YUTREPIA as first-choice prostacyclin across PAH and PH-ILD, targeting dose titration beyond existing inhaled therapies like Tyvaso
• • Quantitative metric: YUTREPIA studied at doses up to 424 mcg QID, significantly higher than 64 mcg max dose for Tyvaso DPI, enabling extended inhaled therapy use
• • Noteworthy filing fact: YUTREPIA developed via 505(b)(2) pathway faces ongoing patent litigation by United Therapeutics seeking FDA approval withdrawal

Risk Factors

• • Cybersecurity risk with potential material disruption of product development programs and financial losses due to IT system failures or data breaches
• • Board Audit Committee oversight of cybersecurity risks with regular management reporting on security controls and incident response effectiveness
• • Dependence on head of IT with 25+ years cybersecurity experience managing day-to-day information security and threat detection operations
• • Incident response led by CEO, CFO, General Counsel, and supported by external legal and cybersecurity advisors to contain and mitigate breaches
• • Potential reputational risk and unauthorized release of confidential information impacting business and financial condition

Management Discussion & Analysis

• • Revenue $158.3M in 2025 vs $14.0M in 2024; product sales $148.3M from YUTREPIA launches, service revenue down 28% to $10.0M
• • Operating loss improved to $(51.4)M in 2025 vs $(121.3)M in 2024; SG&A rose 93% to $157.2M, R&D decreased 18% to $39.3M
• • Best segment: Product sales $148.3M in 2025; worst segment: Service revenue declined 28% to $10.0M
• • Cash $190.7M end 2025; net cash from financing $59.7M; CapEx $4.3M; license payment $2.0M; no buybacks or dividends disclosed
• • Outlook risks: FDA approval maintenance, YUTREPIA commercialization success, pump availability constraint on Treprostinil Injection, high R&D costs for L606 development

What are the latest LQDA SEC filings in 2026?

Liquidia Corp (LQDA) has filed a 10-K annual report on March 5, 2026, a 10-Q quarterly report on May 11, 2026, an 8-K current report on June 17, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.

When did LQDA file its most recent 10-K annual report?

Liquidia Corp (LQDA) filed its most recent 10-K annual report on March 5, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.

How do I view LQDA 10-Q quarterly reports?

Liquidia Corp (LQDA)'s most recent 10-Q quarterly report was filed on May 11, 2026. SignalX displays every LQDA 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.

What 8-K current reports has LQDA filed recently?

Liquidia Corp (LQDA)'s most recent 8-K was filed on June 17, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.

Where can I find LQDA insider trading activity (Form 4)?

SignalX aggregates every LQDA Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.

How often does LQDA file with the SEC?

Liquidia Corp (LQDA) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new LQDA filing with AI-powered analysis.

What is the difference between 10-K, 10-Q, and 8-K SEC filings?

A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs, such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for Liquidia Corp (LQDA).

What is LQDA's SEC CIK number?

Liquidia Corp (LQDA)'s SEC CIK (Central Index Key) number is 1819576. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 1819576 to look up all LQDA filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.

Where can I find LQDA return on equity (ROE) and financial data?

SignalX extracts XBRL financial data from Liquidia Corp (LQDA) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.